Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements

Salima Akter; Md Ataur Rahman; Mohammad Nazmul Hasan; Hajara Akhter; Priya Noor; Rokibul Islam; Yoonhwa Shin; Md Hasanur Rahman; Md Shamim Gazi; Md Nazmul Huda; Nguyen Minh Nam; Jinwook Chung; Sunhee Han; Bonglee Kim; Insug Kang; Joohun Ha; Wonchae Choe; Tae Gyu Choi; Sung Soo Kim

doi:10.3390/cells11040650

Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements

Salima Akter, Md Ataur Rahman, Mohammad Nazmul Hasan, Hajara Akhter, Priya Noor, Rokibul Islam, Yoonhwa Shin, Md Hasanur Rahman, Md Shamim Gazi, Md Nazmul Huda, Nguyen Minh Nam, Jinwook Chung, Sunhee Han, Bonglee Kim, Insug Kang, Joohun Ha, Wonchae Choe, Tae Gyu Choi, Sung Soo Kim

Research output: Contribution to journal › Review article › peer-review

60 Citations (Scopus)

Abstract

Aggressive and recurrent gynecological cancers are associated with worse prognosis and a lack of effective therapeutic response. Ovarian cancer (OC) patients are often diagnosed in advanced stages, when drug resistance, angiogenesis, relapse, and metastasis impact survival outcomes. Currently, surgical debulking, radiotherapy, and/or chemotherapy remain the mainstream treatment modalities; however, patients suffer unwanted side effects and drug resistance in the absence of targeted therapies. Hence, it is urgent to decipher the complex disease biology and identify potential biomarkers, which could greatly contribute to making an early diagnosis or predicting the response to specific therapies. This review aims to critically discuss the current therapeutic strategies for OC, novel drug-delivery systems, and potential biomarkers in the context of genetics and molecular research. It emphasizes how the understanding of disease biology is related to the advancement of technology, enabling the exploration of novel biomarkers that may be able to provide more accurate diagnosis and prognosis, which would effectively translate into targeted therapies, ultimately improving patients’ overall survival and quality of life.

Original language	English
Article number	650
Journal	Cells
Volume	11
Issue number	4
DOIs	https://doi.org/10.3390/cells11040650
Publication status	Published - 1 Feb 2022

Bibliographical note

Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

Angiogenesis
Molecular insight
Ovarian cancer
Technology advances
Therapeutic strategies and targets

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cells11040650

Cite this

Akter, S., Rahman, M. A., Hasan, M. N., Akhter, H., Noor, P., Islam, R., Shin, Y., Rahman, M. H., Gazi, M. S., Huda, M. N., Nam, N. M., Chung, J., Han, S., Kim, B., Kang, I., Ha, J., Choe, W., Choi, T. G., & Kim, S. S. (2022). Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements. Cells, 11(4), Article 650. https://doi.org/10.3390/cells11040650

@article{01ff2f92243e4afdb55860b4fe3eb352,

title = "Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements",

abstract = "Aggressive and recurrent gynecological cancers are associated with worse prognosis and a lack of effective therapeutic response. Ovarian cancer (OC) patients are often diagnosed in advanced stages, when drug resistance, angiogenesis, relapse, and metastasis impact survival outcomes. Currently, surgical debulking, radiotherapy, and/or chemotherapy remain the mainstream treatment modalities; however, patients suffer unwanted side effects and drug resistance in the absence of targeted therapies. Hence, it is urgent to decipher the complex disease biology and identify potential biomarkers, which could greatly contribute to making an early diagnosis or predicting the response to specific therapies. This review aims to critically discuss the current therapeutic strategies for OC, novel drug-delivery systems, and potential biomarkers in the context of genetics and molecular research. It emphasizes how the understanding of disease biology is related to the advancement of technology, enabling the exploration of novel biomarkers that may be able to provide more accurate diagnosis and prognosis, which would effectively translate into targeted therapies, ultimately improving patients{\textquoteright} overall survival and quality of life.",

keywords = "Angiogenesis, Molecular insight, Ovarian cancer, Technology advances, Therapeutic strategies and targets",

author = "Salima Akter and Rahman, {Md Ataur} and Hasan, {Mohammad Nazmul} and Hajara Akhter and Priya Noor and Rokibul Islam and Yoonhwa Shin and Rahman, {Md Hasanur} and Gazi, {Md Shamim} and Huda, {Md Nazmul} and Nam, {Nguyen Minh} and Jinwook Chung and Sunhee Han and Bonglee Kim and Insug Kang and Joohun Ha and Wonchae Choe and Choi, {Tae Gyu} and Kim, {Sung Soo}",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = feb,

day = "1",

doi = "10.3390/cells11040650",

language = "English",

volume = "11",

journal = "Cells",

issn = "2073-4409",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "4",

}

TY - JOUR

T1 - Recent Advances in Ovarian Cancer

T2 - Therapeutic Strategies, Potential Biomarkers, and Technological Improvements

AU - Akter, Salima

AU - Rahman, Md Ataur

AU - Hasan, Mohammad Nazmul

AU - Akhter, Hajara

AU - Noor, Priya

AU - Islam, Rokibul

AU - Shin, Yoonhwa

AU - Rahman, Md Hasanur

AU - Gazi, Md Shamim

AU - Huda, Md Nazmul

AU - Nam, Nguyen Minh

AU - Chung, Jinwook

AU - Han, Sunhee

AU - Kim, Bonglee

AU - Kang, Insug

AU - Ha, Joohun

AU - Choe, Wonchae

AU - Choi, Tae Gyu

AU - Kim, Sung Soo

PY - 2022/2/1

Y1 - 2022/2/1

N2 - Aggressive and recurrent gynecological cancers are associated with worse prognosis and a lack of effective therapeutic response. Ovarian cancer (OC) patients are often diagnosed in advanced stages, when drug resistance, angiogenesis, relapse, and metastasis impact survival outcomes. Currently, surgical debulking, radiotherapy, and/or chemotherapy remain the mainstream treatment modalities; however, patients suffer unwanted side effects and drug resistance in the absence of targeted therapies. Hence, it is urgent to decipher the complex disease biology and identify potential biomarkers, which could greatly contribute to making an early diagnosis or predicting the response to specific therapies. This review aims to critically discuss the current therapeutic strategies for OC, novel drug-delivery systems, and potential biomarkers in the context of genetics and molecular research. It emphasizes how the understanding of disease biology is related to the advancement of technology, enabling the exploration of novel biomarkers that may be able to provide more accurate diagnosis and prognosis, which would effectively translate into targeted therapies, ultimately improving patients’ overall survival and quality of life.

AB - Aggressive and recurrent gynecological cancers are associated with worse prognosis and a lack of effective therapeutic response. Ovarian cancer (OC) patients are often diagnosed in advanced stages, when drug resistance, angiogenesis, relapse, and metastasis impact survival outcomes. Currently, surgical debulking, radiotherapy, and/or chemotherapy remain the mainstream treatment modalities; however, patients suffer unwanted side effects and drug resistance in the absence of targeted therapies. Hence, it is urgent to decipher the complex disease biology and identify potential biomarkers, which could greatly contribute to making an early diagnosis or predicting the response to specific therapies. This review aims to critically discuss the current therapeutic strategies for OC, novel drug-delivery systems, and potential biomarkers in the context of genetics and molecular research. It emphasizes how the understanding of disease biology is related to the advancement of technology, enabling the exploration of novel biomarkers that may be able to provide more accurate diagnosis and prognosis, which would effectively translate into targeted therapies, ultimately improving patients’ overall survival and quality of life.

KW - Angiogenesis

KW - Molecular insight

KW - Ovarian cancer

KW - Technology advances

KW - Therapeutic strategies and targets

UR - http://www.scopus.com/inward/record.url?scp=85124351067&partnerID=8YFLogxK

U2 - 10.3390/cells11040650

DO - 10.3390/cells11040650

M3 - Review article

C2 - 35203301

AN - SCOPUS:85124351067

SN - 2073-4409

VL - 11

JO - Cells

JF - Cells

IS - 4

M1 - 650

ER -

Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this